Wedbush Reaffirms “Outperform” Rating for Pacira BioSciences (NASDAQ:PCRX)

Wedbush reaffirmed their outperform rating on shares of Pacira BioSciences (NASDAQ:PCRXFree Report) in a research report released on Thursday morning, Benzinga reports. They currently have a $57.00 price objective on the stock.

PCRX has been the subject of a number of other reports. HC Wainwright lowered their price target on Pacira BioSciences from $63.00 to $57.00 and set a buy rating for the company in a report on Monday, November 6th. TheStreet downgraded Pacira BioSciences from a c rating to a d+ rating in a report on Thursday, November 2nd. Barclays lowered their price target on Pacira BioSciences from $60.00 to $57.00 and set an overweight rating for the company in a report on Monday, October 23rd. Piper Sandler lowered their price target on Pacira BioSciences from $50.00 to $42.00 and set an overweight rating for the company in a report on Friday, November 3rd. Finally, Needham & Company LLC decreased their price objective on Pacira BioSciences from $52.00 to $45.00 and set a buy rating for the company in a report on Friday, November 3rd. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat, Pacira BioSciences presently has an average rating of Buy and an average price target of $51.44.

View Our Latest Analysis on PCRX

Pacira BioSciences Stock Performance

Shares of Pacira BioSciences stock opened at $28.78 on Thursday. Pacira BioSciences has a one year low of $25.93 and a one year high of $48.60. The company has a market cap of $1.34 billion, a PE ratio of 319.78 and a beta of 0.79. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.74 and a current ratio of 4.78. The business has a 50-day simple moving average of $31.58 and a 200-day simple moving average of $31.95.

Institutional Investors Weigh In On Pacira BioSciences

Several large investors have recently modified their holdings of PCRX. Financial Freedom LLC purchased a new stake in shares of Pacira BioSciences during the fourth quarter worth approximately $33,000. ICA Group Wealth Management LLC purchased a new position in Pacira BioSciences in the fourth quarter worth $35,000. China Universal Asset Management Co. Ltd. raised its position in Pacira BioSciences by 96.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,185 shares of the company’s stock worth $36,000 after acquiring an additional 583 shares in the last quarter. Neo Ivy Capital Management purchased a new position in Pacira BioSciences in the second quarter worth $44,000. Finally, Nisa Investment Advisors LLC raised its position in Pacira BioSciences by 310.9% in the third quarter. Nisa Investment Advisors LLC now owns 2,001 shares of the company’s stock worth $61,000 after acquiring an additional 1,514 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

(Get Free Report)

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.

Read More

Analyst Recommendations for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.